Continued FDA approval of iptacopan was contingent on 2-year trial data ...

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial ...

Calliditas Therapeutics AB, an Asahi Kasei company, announced today that new data from the Phase 3 NefIgArd study in patients with primary immunoglobulin A nephropathy (IgAN) will be presented at the ...

Between 20 and 50 percent of individuals with IgA nephropathy will experience kidney failure within two decades of diagnosis, though the timeline varies significantly from person to person. Regular ...

Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta ® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, ...

Earlier in March 2026, Vertex Pharmaceuticals reported positive pre-specified Week 36 interim Phase 3 RAINIER data for ...

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

Robert Burakoff, MD, MPH, is a board-certified gastroenterologist who serves as vice chair of Ambulatory Services at Lower Manhattan Hospital and professor of medicine at the Weill Cornell Medical ...

David Ozeri, MD, FACP, FACR, is a rheumatologist and current researcher at Sheba Medical Center in Israel. He worked at Kings County Hospital Center and treated veterans at New York Harbor Healthcare ...